139 related articles for article (PubMed ID: 11747323)
1. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.
Torrisi R; Baglietto L; Johansson H; Veronesi G; Bonanni B; Guerrieri-Gonzaga A; Ballardini B; Decensi A
Br J Cancer; 2001 Dec; 85(12):1838-41. PubMed ID: 11747323
[TBL] [Abstract][Full Text] [Related]
2. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.
Lasco A; Gaudio A; Morini E; Morabito N; Nicita-Mauro C; Catalano A; Denuzzo G; Sansotta C; Xourafa A; Macrì I; Frisina N
Menopause; 2006; 13(5):787-92. PubMed ID: 16912660
[TBL] [Abstract][Full Text] [Related]
3. Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer.
Eng-Wong J; Hursting SD; Venzon D; Perkins SN; Zujewski JA
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1468-73. PubMed ID: 14693739
[TBL] [Abstract][Full Text] [Related]
4. Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study.
Duschek EJ; de Valk-de Roo GW; Gooren LJ; Netelenbos C
Fertil Steril; 2004 Aug; 82(2):384-90. PubMed ID: 15302288
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.
Johansson H; Baglietto L; Guerrieri-Gonzaga A; Bonanni B; Mariette F; Macis D; Serrano D; Sandri MT; Decensi A
Breast Cancer Res Treat; 2004 Nov; 88(1):63-73. PubMed ID: 15538047
[TBL] [Abstract][Full Text] [Related]
6. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial.
Fairey AS; Courneya KS; Field CJ; Bell GJ; Jones LW; Mackey JR
Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):721-7. PubMed ID: 12917202
[TBL] [Abstract][Full Text] [Related]
7. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.
Lawrence JB; Conover CA; Haddad TC; Ingle JN; Reid JM; Ames MM; Suman VJ; Marks RS; Erlichman C; Hartmann LC
Clin Cancer Res; 1997 Oct; 3(10):1713-20. PubMed ID: 9815555
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer.
Fürstenberger G; Senn E; Morant R; Bolliger B; Senn HJ
Breast; 2006 Feb; 15(1):64-8. PubMed ID: 15998587
[TBL] [Abstract][Full Text] [Related]
10. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
[TBL] [Abstract][Full Text] [Related]
11. Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer.
Johansson H; Bonanni B; Mariette F; Cazzaniga M; Baglietto L; Guerrieri-Gonzaga A; Sandri MT; Luini A; Pelosi G; Decensi A
Breast Cancer Res Treat; 2006 Jul; 98(2):167-72. PubMed ID: 16538534
[TBL] [Abstract][Full Text] [Related]
12. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study.
Kahán Z; Gardi J; Nyári T; Földesi I; Hajnal-Papp R; Ormándi K; Lázár G; Thurzó L; Schally AV
Int J Oncol; 2006 Jul; 29(1):193-200. PubMed ID: 16773200
[TBL] [Abstract][Full Text] [Related]
13. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factors and breast cancer risk in Chinese women.
Yu H; Jin F; Shu XO; Li BD; Dai Q; Cheng JR; Berkel HJ; Zheng W
Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):705-12. PubMed ID: 12163322
[TBL] [Abstract][Full Text] [Related]
15. Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women.
Grønbaek H; Flyvbjerg A; Mellemkjaer L; Tjønneland A; Christensen J; Sørensen HT; Overvad K
Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1759-64. PubMed ID: 15533904
[TBL] [Abstract][Full Text] [Related]
16. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
Heald A; Kaushal K; Anderson S; Redpath M; Durrington PN; Selby PL; Gibson MJ
Gynecol Endocrinol; 2005 Mar; 20(3):176-82. PubMed ID: 16019358
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
Krajcik RA; Borofsky ND; Massardo S; Orentreich N
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
[TBL] [Abstract][Full Text] [Related]
18. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
[TBL] [Abstract][Full Text] [Related]
19. Dietary determinants of circulating insulin-like growth factor (IGF)-I and IGF binding proteins 1, -2 and -3 in women in the Netherlands.
Vrieling A; Voskuil DW; Bueno de Mesquita HB; Kaaks R; van Noord PA; Keinan-Boker L; van Gils CH; Peeters PH
Cancer Causes Control; 2004 Oct; 15(8):787-96. PubMed ID: 15456992
[TBL] [Abstract][Full Text] [Related]
20. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
Bevers TB
J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
